Rev02
Update: Aug,08,2025

DATASHEET

HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Biotin], His & Avi, Cynomolgus

Cat. No.: Z06458

Product Introduction

Species	Cynomolgus
Protein Construction	
Conjugate	Biotin
Purity	> 95% as determined by BisTris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per μg by the LAL method.
Biological Activity	Cynomolgus LILRB2, hFc Tag captured on CM5 Chip via Protein A can bind HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Biotin], His & Avi, Cynomolgus in SPR assay (Biacore T200). Test result was comparable to standard batch.
Expression System	HEK293
Theoretical Molecular Weight	50.6 kDa
Apparent Molecular Weight	Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background

Target Background : HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition.

Synonyms : HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC-G; sHLA-G

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China